Notable Reporting: Could Acceleron Pharma Inc Rise Even More? The Stock Had Another Big Increase Today

Notable Reporting: Could Acceleron Pharma Inc Rise Even More? The Stock Had Another Big Increase Today

The stock of Acceleron Pharma Inc (NASDAQ:XLRN) is a huge mover today! About 152,435 shares traded hands. Acceleron Pharma Inc (NASDAQ:XLRN) has risen 12.39% since March 7, 2016 and is uptrending. It has outperformed by 4.80% the S&P500.
The move comes after 6 months positive chart setup for the $1.30 billion company. It was reported on Oct, 10 by Barchart.com. We have $57.56 PT which if reached, will make NASDAQ:XLRN worth $832.00M more.

Analysts await Acceleron Pharma Inc (NASDAQ:XLRN) to report earnings on November, 2. They expect $-0.57 EPS, down 58.33% or $0.21 from last year’s $-0.36 per share. After $-0.59 actual EPS reported by Acceleron Pharma Inc for the previous quarter, Wall Street now forecasts -3.39% EPS growth.

Acceleron Pharma Inc (NASDAQ:XLRN) Ratings Coverage

Out of 7 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Acceleron Pharma has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The rating was maintained by Barclays Capital on Monday, June 13 with “Overweight”. The rating was maintained by FBR Capital on Monday, January 18 with “Outperform”. The stock has “Overweight” rating given by Morgan Stanley on Thursday, August 13. Janney Capital initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Thursday, December 17 with “Neutral” rating. FBR Capital maintained Acceleron Pharma Inc (NASDAQ:XLRN) on Friday, January 15 with “Outperform” rating. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. Citigroup initiated it with “Neutral” rating and $40 target price in Thursday, September 29 report. As per Wednesday, April 27, the company rating was initiated by Barclays Capital. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) earned “Outperform” rating by Oppenheimer on Friday, November 20. The firm has “Outperform” rating by Oppenheimer given on Monday, February 1.

According to Zacks Investment Research, “Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1.49 in Q2 2016. Its down 0.65, from 2.14 in 2016Q1. The ratio turned negative, as 15 funds sold all Acceleron Pharma Inc shares owned while 32 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 28.02 million shares or 2.80% less from 28.83 million shares in 2016Q1.
Vanguard Group Incorporated holds 1.65 million shares or 0% of its portfolio. Oak Ridge Ltd Liability accumulated 1.17% or 1.34M shares. Franklin Resources holds 0.01% or 494,777 shares in its portfolio. Hamilton Lane Advsr Ltd Liability Corp reported 33,340 shares or 0.55% of all its holdings. Atika Capital Ltd accumulated 0.35% or 24,000 shares. Sei Invs Co has invested 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). State Bank Of America De has 46,325 shares for 0% of their US portfolio. Moreover, Principal Grp Inc has 0% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 97,100 shares. Wells Fargo Commerce Mn, a California-based fund reported 23,483 shares. Pictet Asset Mgmt Limited owns 727,427 shares or 0.1% of their US portfolio. Amer Interest Group last reported 15,777 shares in the company. Ubs Asset Mngmt Americas last reported 0% of its portfolio in the stock. Moreover, Voya Management Limited has 0% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 11,582 shares. Sectoral Asset Mngmt Incorporated has 522,294 shares for 1.83% of their US portfolio. Qvt Fincl L P accumulated 702,410 shares or 1.64% of the stock.

Insider Transactions: Since May 18, 2016, the stock had 0 insider buys, and 9 selling transactions for $43.32 million net activity. Ertel Steven D also sold $1.12M worth of Acceleron Pharma Inc (NASDAQ:XLRN) on Friday, July 1. MCLAUGHLIN KEVIN F also sold $876,898 worth of Acceleron Pharma Inc (NASDAQ:XLRN) on Friday, July 1. Sherman Matthew L sold $903,143 worth of stock. 857,145 Acceleron Pharma Inc (NASDAQ:XLRN) shares with value of $30.43M were sold by George Jean. The insider Quisel John D sold 21,438 shares worth $689,017. On Wednesday, May 18 Knopf John L sold $3.31M worth of the stock or 100,000 shares.

More news for Acceleron Pharma Inc (NASDAQ:XLRN) were recently published by: Marketwatch.com, which released: “Acceleron Pharma tabs Bayer exec as next CEO” on September 27, 2016. Marketwatch.com‘s article titled: “Virtual Stock Exchange” and published on September 19, 2013 is yet another important article.

XLRN Company Profile

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. The Firm focuses on discovering and developing therapeutic candidates that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment